Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

rAAV2/5-hNAGLU

Gene therapy (AAV vector) · Gene replacement · developed by UniQure Biopharma B.V.

Phase 1/2 Most advanced trial (none active)
QURE Developer
1 Registered trials

What is rAAV2/5-hNAGLU?

rAAV2/5-hNAGLU is an AAV5-based gene therapy carrying the human NAGLU gene, delivered by one-time intraparenchymal injection into the brain. It is studied in Sanfilippo syndrome type B (mucopolysaccharidosis III), a lysosomal storage disease caused by NAGLU deficiency.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AAV5
Drug type
Gene therapy (AAV vector)
Mechanism
Gene replacement
Therapy area
Metabolic
Developer
UniQure Biopharma B.V. (QURE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03300453 Phase 1/2 Sanfilippo Syndrome B Completed QURE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Sanfilippo Syndrome B

More from UniQure Biopharma B.V.

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the QURE page.

Follow QURE, the company behind rAAV2/5-hNAGLU

See QURE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

QURE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.